RAPS: FDA Approves First Drug to Improve Overall Survival in Liposarcoma

FDA Approves First Drug to Improve Overall Survival in Liposarcoma The US Food and Drug Administration (FDA) on Thursday approved a new indication for Eisai\'s Halaven (eribulin mesylate) to treat liposarcoma, a rare and deadly form of soft tissue sarcoma (STS) that affects only a few thousand patients in the US each year. FDA said Halaven is approved to treat liposarcoma that cannot be operated on, or has metastasized in patients who have already undergone chemotherapy.